NextCure, Inc.
9000 Virginia Manor Rd. Suite 200
Beltsville
MD
20705
United States
Tel: (240)399-4900
Website: https://www.nextcure.com/
Email: Info@NextCure.com
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.
Cancer is a complex disease where cells in the tumor microenvironment promote tumor progression, immune evasion and suppression of anti-tumor immune responses. While therapies targeting inhibitory or immune checkpoint molecules have shown important success in many cancers, not all patients benefit from these therapies (non-responders), and many develop resistance after initial treatment. NextCure is identifying novel tumor-specific interactions and mechanisms of immune regulation to generate a sustainable product pipeline to address these patients in need.
NextCure brings significant experience and innovation in cancer immunology. The company’s FIND-IOTM technology provides a large repertoire of function-based screens and imparts a unique understanding of cell surface molecular interactions between immune and diseased cells. We are using this important knowledge to rapidly develop and advance novel biologics that impact suppressive myeloid cell populations, T cell subsets, and other cell populations within the tumor microenvironment to restore anti-tumor activity and improve clinical response rates and outcomes for patients.
Stock Symbol: NXTC
Business Spotlight - Nextcure
89 articles about NextCure, Inc.
-
NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer
7/13/2020
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, provided an interim update for the Phase 2 portion of its NC318 monotherapy phase 1/2 trial.
-
NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors
7/7/2020
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC410, a novel immunomedicine developed to block immune suppression mediated by an immune modulator called LAIR-1.
-
NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting
5/29/2020
NextCure, Inc. announced the presentation of biomarker data and updated clinical results from the Phase 1 portion of its ongoing Phase 1/2 monotherapy trial with NC318 at the 2020 Virtual American Society of Clinical Oncology Annual Meeting.
-
NextCure Reports First Quarter 2020 Financial Results
5/7/2020
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported first quarter 2020 financial results and provided a business update.
-
NextCure to Present at BofA Securities Virtual Health Care Conference
5/6/2020
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will present at the BofA Securities Virtual Health Care Conference on May 13th at 9:00 am Eastern time.
-
NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic
4/13/2020
NextCure, Inc. provided an update on the company's clinical trial activities due to the impact of the COVID-19 pandemic.
-
NextCure to Present at the 19th Annual Needham Virtual Healthcare Conference
4/8/2020
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will present at the 19th Annual Needham Virtual Healthcare Conference on April 15th at 2:10 pm Eastern time.
-
NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors
3/30/2020
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced the appointment of Garry Nicholson to its board of directors.
-
NextCure Reports Fourth Quarter and Full Year 2019 Financial Results
3/12/2020
NextCure, Inc. reported fourth quarter and full year 2019 financial results and provided a business update.
-
NextCure to Present at the 40th Annual Cowen Health Care Conference
2/25/2020
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 40th Annual Cowen Health Care Conference in Boston on March 4 at 8:00 am.
-
NextCure to Present at 9th Annual SVB Leerink Global Healthcare Conference
2/18/2020
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York on February 25 at 9:00 am.
-
NextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/6/2020
NextCure, Inc. announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020, in San Francisco, California.
-
NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference
11/26/2019
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that the company will present at the Piper Jaffray 31st Annual Healthcare Conference in New York on December 3, 2019 at 2:00 pm ET.
-
NextCure Announces Closing of Public Offering
11/19/2019
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share.
-
NextCure Announces Pricing of Public Offering of Common Stock
11/15/2019
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share
-
NextCure Reports Third Quarter 2019 Financial Results
11/12/2019
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2019 financial results and provided a business update.
-
NextCure Announces Proposed Public Offering of Common Stock
11/12/2019
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced a proposed public offering of 3,200,000 shares of its common stock.
-
NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/4/2019
NextCure, Inc. announced that the company will host and webcast an event with its Chief Medical Officer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer on Saturday, November 9, 2019 at 6:30 p.m. Eastern Time at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.
-
A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
-
Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.